Waldman

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
Saturday, March 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Retrieved on: 
Tuesday, March 5, 2024
Paragon, Well, SAD, PD, Injection, I&I, Waldman, Headache, Inflammation, Quality of life, Management, Atopic dermatitis, Asthma, TARC, AUC, Volunteering, Cmax, Chronic obstructive pulmonary disease, Outline of health sciences, Safety, Biomarker, Therapy, CQD, Chronic pain, Immunology, IGA, Webcast, Sleep, Patient, MPH, Half-life, Serum, Pharmaceutical industry

Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.

Key Points: 
  • Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.
  • At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients.
  • The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate safety and PK of APG777 in healthy volunteers.
  • A live webcast of the call will be available on the Investor Relations page of Apogee’s website at https://investors.apogeetherapeutics.com/news-events/events .

RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis

Retrieved on: 
Monday, March 28, 2022
Therapy, AD, Waldman, Inflammation, Immunology, Mount Sinai, Icahn School of Medicine at Mount Sinai, GLOBE, American Academy, SAN, Patient, Pharmaceutical industry, Dermatology

These biomarker data were derived from biopsies taken from the lesional and non-lesional skin of patients enrolled in the Phase 1b trial.

Key Points: 
  • These biomarker data were derived from biopsies taken from the lesional and non-lesional skin of patients enrolled in the Phase 1b trial.
  • Brian Wong, M.D., Ph.D., President and CEO of RAPT, added, We thank Dr. Guttman and her lab for the rigorous evaluation of patient samples from our Phase 1b trial of RPT193 in atopic dermatitis.
  • We look forward to initiating our Phase 2b clinical trial in atopic dermatitis and to expanding our exploration of RPT193 in a Phase 2a trial in asthma.
  • The Phase 1b trial was part of a combined Phase 1a/1b clinical study of RPT193.

Data Center Infrastructure Visionary Eyal Waldman Joins Pliops Board of Directors

Articles, Computer memory, Waldman, Flash memory, Information technology, Innovation, Computing, Science and technology

SAN JOSE, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Technology innovator Pliops today announced that Eyal Waldman has joined its board of directors.

Key Points: 
  • SAN JOSE, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Technology innovator Pliops today announced that Eyal Waldman has joined its board of directors.
  • Pliops is tackling the most challenging issues that are vexing to data center architects namely, the colliding trends of explosive data growth stored on fast flash media, ultimately limited by constrained compute resources, noted Waldman.
  • In his role as a Pliops board member, Waldman will help guide the companys growth and scale its technology into new use cases.
  • Pliops technology is also set to revolutionize the way that data and storage are managed in the data center.

Leaf Group Names Alan Waldman Executive Vice President, Product & Technology

Retrieved on: 
Tuesday, September 10, 2019
Leaf Group, Brand, Waldman, Marketing, Market economics), Business

Waldman will serve as Executive Vice President, Product & Technology, overseeing strategy and execution of the product and engineering teams for Leaf Groups marketplace brands.

Key Points: 
  • Waldman will serve as Executive Vice President, Product & Technology, overseeing strategy and execution of the product and engineering teams for Leaf Groups marketplace brands.
  • Ive known Alan for years and have always been impressed with his business instincts and ability to energize his team, said Sean Moriarty, CEO of Leaf Group.
  • In his role at Leaf Group, Waldman will oversee the marketplace product and engineering teams, with a focus on growth strategies for Society6.
  • Im thrilled to be joining Leaf Group and working with such vibrant marketplace brands, said Alan Waldman.

Waldman & Schantz Plastic Surgery and Skin Care Welcomes New Partner

Retrieved on: 
Thursday, September 27, 2018
Germanic peoples, Finnish nobility, German nobility, Russian nobility, Schantz, Swedish nobility, Waldman, European people, Europe

LEXINGTON, Ky., Sept. 27, 2018 /PRNewswire-PRWeb/ -- After three years with Waldman & Schantz, J. Brad Turner, MD has earned the title of practicing partner, officially changing the clinic's name to Waldman, Schantz & Turner Plastic Surgery.

Key Points: 
  • LEXINGTON, Ky., Sept. 27, 2018 /PRNewswire-PRWeb/ -- After three years with Waldman & Schantz, J. Brad Turner, MD has earned the title of practicing partner, officially changing the clinic's name to Waldman, Schantz & Turner Plastic Surgery.
  • Prior to joining Central Kentucky's premier plastic surgery group, Dr. Turner completed a 6-year plastic surgery residency at the University of Kentucky.
  • Both Dr. Waldman and Dr. Schantz are pleased to officially welcome Dr. Turner as a practicing partner.
  • Contact Dr. Turner at Waldman, Schantz & Turner Plastic Surgery Center and Skin Care in Lexington, KY at (859) 254-5665, or through the Contact Us form.